Eisai and Biogen have announced UK MHRA approval for Leqembi for intravenous (IV) maintenance dosing to treat early Alzheimer ...

Viehbacher, “Biogen”) announced today that humanized anti- soluble aggregated amyloid-beta (Aß) monoclonal antibody “LEQEMBI ® ” (generic name: lecanemab) has been approved for once every four weeks ...

Treatment Market is projected to grow at a healthy rate of around 13% by 2026. This growth is primarily driven by the ...

Oral presentation to share first-of-its-kind longitudinal gene expression data in IgA nephropathy, unveiling novel insights into the mechanism of ...

With $185 million in series A funding and an army of experienced leaders in its ranks, Braveheart Bio is setting off to joust ...

DelveInsight's Antibody-mediated Rejection Market Insights report includes a comprehensive understanding of current treatment ...

The startup is advancing a drug licensed from China’s Hengrui Pharma that it claims could be “best-in-class” among a group of similar treatments for hypertrophic cardiomyopathy.

Biogen Inc. (($BIIB)) has held its Q3 earnings call. Read on for the main highlights of the call. Biogen Inc. recently held its earnings call, ...

Biogen Inc. cut its full-year profit guidance on higher costs from deals the company has been doing to offset the decline of its aging multiple sclerosis drugs.

Patients with stroke who receive intra-arterial thrombolysis after thrombectomy are more likely to achieve superior 90-day ...